The top 10 adverse events reported to the FDA FAERS database for Glucagon-Like Peptide-1 (GLP-1) Analogues are Nausea, Blood glucose increased, Weight decreased, Injection site pain, Vomiting, Decreased appetite, Diarrhoea, Injection site haemorrhage, Blood glucose decreased, and Product dose omission issue.
The distribution of these adverse events among the drugs marketed in this drug group are shown in the graph below. The Proportional Reporting Ratio (PRR) of these adverse events among Glucagon-Like Peptide-1 (GLP-1) Analogues drugs are also included to analyze the disproportional ratio. The data used in the calculation includes all adverse event reports submitted to FAERS for the Glucagon-Like Peptide-1 (GLP-1) Analogues from 2004 Q1 to 2024 Q3. Further analysis is required to confirm the potential signal for any of these drug-adverse events.
Comments